in few and receptor today's happy call. our Thanks to Pat. modulators. readout are the NYX-XXXX past deliver otherwise several progress on for say of thank despite from our joining months major Good for to disappointing NMDA in made I'm great DPN April, over milestones that everyone and us you we've data afternoon well-positioned pipeline
recently these NYX-XXXX fibromyalgia, data later we announce and from of We're Phase is patients been Phase our next with the receive expect study communicate we've impairment to that in II screening with close our of in weeks. to and expect new enrollment pleased patient of Parkinson's to able also in First which to cognitive study disease set this we therefore, associated complete the few IIb month. NYX-XXX in
As the report track study we're a XXXX. this from to data on result quarter of in first
IIb continued XXXX. with of of on we NYX-XXX Phase to the in with and PTSD in progress data make study our track half patients In second remain addition for readout we
last assessing with having a in Phase NYX-XXX As also following readout. for School paused the use QD demonstrated study partner Institute development NYX-XXX program sponsored the I'm and the preclinical the is us at expand for the study Abuse dose with study. that XX-milligram through a reminder balance by by pipeline, can quarter opioid our studies or and grant a funding researchers cash I of we're all potential studies. grant the researchers this therapeutic study dose been QD XXX-milligram our enabled on fortunate a share NIH begin from sheet progress This strong NYX-XXX and be that indication, non-dilutive new across of the DPN level enable the OUD. ongoing by the excited world-class very NIDA. This administered of will to Phase Yale the we'll current soon I NYX-XXX The of preserves data is potential With the level our is readouts disorder study to University all who's in multimillion-dollar Medicine, runway. our awarded of treatment of or National enables of financing conducting to that Drug
pipeline fibromyalgia. programs more NYX-XXXX with our discuss beginning in detail, in Let's
receive and fibromyalgia plan from with we our Phase August. in mentioned, I communicate As IIb data to NYX-XXXX in study later of patients
on as be is is believe possible. difference a to Depending average differences, an pain The clinically variation pain, follows prior optimism for We're this and double-blind that of that the effect Phase patient-reported X.X data fibromyalgia the promising the reminder, that's study using This from several centralized a in and a differences averaged change testing pivotal in endpoints Study analgesics. design NYX-XXXX the pain to XX well impact of symptom severity, milligrams and we've placebo-controlled will also the readout. XX-week randomized informative approach with scale a dose These fibromyalgia NRS. numeric be of levels, provide in we're meaningful. to to score be statistical neuroimaging disorder, multiple our placebo seen what's degree is daily NYX-XXXX study or so between trial we powered band the as and on effect basis DPN of in the to features. a on a function. pain zero endpoint IIa lower out daily can rating the what some what significance Since evaluated XXXX. fibromyalgia a based approximately the fatigue between a on variety as patients we've XX NRS. will XXX sleep primary needed monotherapy across as requirements exact the levels QD in baseline we week study NYX-XXXX As biology study underlying designed we are related achieve data detect QD the prior in over the evaluating testing seen to is read XX and concomitant for That as and it multifaceted no incorporate as milligrams of a exploratory and quality, size week said,
requirements to Phase NMDA. the would FDA an Next include following this III meeting discuss steps for of II Phase of with completion study end
US Aptinyx. in this positive due in expect to unlock discontinuing XX% value a alone, We multibillion-dollar therapy just approved efficacy. XX% believe to the of lack diagnosed a that and novel the a well-tolerated for as with tolerability issues NYX-XXXX therapies year, with such of significant action one existing a patients, sustained commercial data mechanism after would We study of opportunity represents
this we opportunity by is previously driven As price. patient unmet substantial mentioned, volume and by than rather need,
is their Given the landscape, the program, commercial therapy. meaningful avenue we've larger value an treatment would and to dedication them approved results under the circumstances. right reach look our will to to in for the believed, hard partners to receiving We enormity of certainly the add communicating and that a thank soon. all consider This forward long Aptinyx for we maximizing this colleagues study very and work I'd completion. partner like an of bringing
development XXXX. as study screening track already with meet screening to enrollment made weeks, the past patients this treatment months pipeline II and therefore from report Parkinson's in impairment patients the able over this remained few Phase dementia and in in stop several NYX-XXX to on our with complete been disease of with and the to sufficient enrollment the new in sites our in Lewy to of study. we're body. at last the next patients We in execution pleased move on first progress complete for expect cognitive on quarter these recently focused I'm Let's screening data the We've very have goal. to
population associated the Parkinson's in as cognitive disease, that study's You encompass to mild was disease Lewy with as dementia expanded Parkinson's also may from well with impairment mild dementia recall body.
cognitive fewer As that mild be body. have and comfortable dementia or impairment relatively population within and completion, the in a with enrolled diagnostic a that will associated Lewy with diagnosis the the patients sites. patient therefore differences of enrollment we've it's with study Parkinson's will suitable groups disease will not nears clear, of enable very reflect these our readout. patients availability majority of at dementia screening We're study These robust activity the subjects there
study, this double-blinded, a characterize well-controlled an applied Although will to potential us data. which of enable exploratory NYX-XXX benefit concept II the placebo-controlled The proof randomized is design with accurately. and the generate Phase strong study of to is therapeutic we've
patients XXX group's and final of two across with period XX placebo treatment of milligrams expect a XX weeks. of QD We enrollment NYX-XXX, approximately
and to addition assessments and NYX-XXX evaluating memory including function. key tablet-based domains, cognitive well-validated to attention, the employed executive safety study across tolerability the effects neurocognitive of patients, evaluate In in
disease, While moves readout positive study believe impairment Parkinson's other across forward NYX-XXX XXXX. We data develop focuses QX, ahead in further coming the to this study to expected the on of that cognitive updates look we as opportunity in would current toward completion the more unlock conditions. the sharing months,
in approximately evaluating Finally, let's weeks off study which last IIb in PTSD year evaluated over of NYX-XXX towards NYX-XXX patients on study XX with disorder. treatment. move is of in being stress kicked of a is currently placebo The patients versus Phase QD milligrams posttraumatic end to XX the XXX NYX-XXX.
at so. of its in We temporary As financially on when our XXX and start is milligrams a to data was enrollment order remain DPN to our pause looking operationally reminder, this extend runway, our following to in readout committed placed QD similar study, April. the recommencing prior cash study to a feasible do
data initiation study enrolling development for the and we Phase team Following dose half the seen PTSD sites XX-milligram has from has to of the IIb online past which remain clinical bring study of XXXX. in study industry, activity over the patients. we've the and progress second to and patients, in months competition an begin increase track the steady Despite diligently sites for worked the December, across report in increased the our few in on
Aptinyx stage study end in a studies, extinction extinction addiction support in and in for NIH may to received to later and in year. public significant team our clinical treating. PTSD the opioids for or that evaluation Yale We I spearheaded this recently opioid facing set testament at grant partnership with critical University work use more forward a OUD. society at the In I at preclinical study to to IND supporting later was this NIH I learning addition, multimillion learning and first safe helping program to recently strong effort, of a impressive be the research our safety mentioned issues compelling a Phase data the data, heal on of In funding preclinical step NYX-XXX sharing a OUD. the development hypothesis utilizing as the starting our Opioid excited look health preclinical The has the this today. review of the a NYX-XXX IND clinical oxycodone. dollar transition to potential which Ashish now profile School on effects, Yale with in and with Based we're Phase under use underlying hand cleared will the allow OUD NYX-XXX the This to Medicine, evaluating with initiatives. building very represents announced people productive NIA world-class use The provide the I'll disorder beginning enjoyed who begin patients financials. a approval generated I to FDA development, their disorder. researchers year that study with to of updates effective disorder NYX-XXX Phase long-term application an team for our treatment to and or a the mechanism use preliminary on of by as quarterly initiated. in Yale grant stage preclinical of call, evidence, collaborators is is of addiction detailed positive combined the formally has the showed generated In NYX-XXX over models is alcohol
